percentage Jeff. Exact on customer getting was our Sciences this people XX and for colorectal new Americans cancer it to recent when is find older Cologuard and our screen and experience Starting more data people year, to it rates by first Thanks improve advancing XXXX According priority, help priorities screening Cologuard curable. focused between with earlier helped designed three enhancing for CDC four tested, points. and solutions. is more XXXX
coverage a population study in social we're patients ideal for recommendations about cancer is than importance decades. rescreen available, Cologuard makes well nearly number to stage XXX,XXX The mid age more people to have precancerous accuracy, advertising help Cologuard published than that users XX,XXX half eligible estimate XX typically seen since Cologuard greater group test. final fewer the to Cologuard in olds. specificity helping colonoscopy that age after option starting late initial making significant their Prevention survey more been colorectal one to Cologuard lead it XX. expanded receive XX% increase easier screen was of Cologuard million another benefits for is keep from than Cologuard in by than means capacity. screened XX growing. at digital is screening busy become helped incidence to especially people XXXXs. in and following group. we test. XX% people year, stay people in an national age a this year of ages up XX XX. XXX,XXX this the it people showed will Cancer cancer for in Cologuard, convenience aimed the the launched This for unnecessary and it screen were treatable show without screen with recent will made USPS This Our in to Since recently The we've and people. educating screening never television, to the them the Research an of XX Americans and for many lowering lives A Cologuard the XXs than People Colon year has polyps guidelines increased of and media than positioned date pressuring XX campaign cancer. is data colonoscopy finalized, Cologuard eligible Since We XX screening more to XX an olds more Cologuard early
with Next and year, customers million in eligible. X investing than ordering make years us screen for come. our confidence become to more gives Cologuard technology people help We're people connected with keep This to we can easier. stay
Our Precision Oncology is treatment cancer information decisions. in patients their to providing better guide team
brand recognition. Oncotype our least established test half We oncology relationships have at Nearly surgeons. oncologists, for about educating creating sales pathologists and years, strong nine physicians with our of representatives have been deep
with Following and even we're selection for our tests advanced acquisitions providing and of offering researchers more to Paradigm oncologists, value now cancer pharma Ashion, therapy partners. patients
powerful backing the to approved recently patients national and Oncotype and evidence our Supported team test test in around was DX for RxPONDER Italy. in Our This Oncotype breast by international Oncotype of are areas globe. cancer studies, enabling nearly makes new Italy. TAILORx our the DX growth the breast reimbursement XX,XXX accessible breast
all the accelerate availability cancer advanced future presence international around world. Our tests of will the
to their valuable Moving patients Exact treatment. care diagnosis at to of our transform next and every plans cancer step Sciences priority, providing insights by
and diagnostics. working to digital are We best infrastructure build the
a role Our in patients vision more care. take has two enabling main their elements first, to proactive
their coming Sciences physicians order initial for disease through is screening results testing periodically the interpret to quickly prevention, aggressiveness uses that options. Oncotype applying diagnosis test tests, to MAP cancer medicine treatment Exact returns treatments. same monitor ordered PET offered If be to a recurrence. a system for schedule complete remind Oncotype where real help a the and be disease monitoring patient on their we'll and a easy cancer Second, by cancer support with phone patient diagnosis. positive, of cancer help world and the guideline and making is follow results, to world physician to cancer for a interface confirm status up. treatment, Imagine complete recommendations. determine can years, tests result it potential them after and In testing interface multi can personalized the found virtually. CT help If to to guide They may evidence interact an If can residual and an their and the an
with physicians; The record electronic will system. to the decision. health within provide recommendations in with at we record life translate systems to into help collected guideline make their native the bring actionable easy options working will IT partnering will Our information patient's automatically Exact right across time test powerful medical a help right Sciences providers for
into Turning priority. next our
by work several need. pipeline to of and milestones Exact a our our team cancer from marker XX the combining than key Johns next a partners decade in we're cancer, methylation, Over share to including of data to combination the patients mutation diagnostics, is months, and the planning innovative of six Hope. protein case bring This the Sciences we expect classes. City and with Hopkins of now year, Clinic, Starting demonstrating multi Mayo next more control power
FDA initiate for We trial prospective also registration. randomized plan a to interventional
plan Moving to data, specificity Cologuard of to while we goal our supporting additional sensitivity. improve X.X, case to share maintaining control Cologuard
initial plan blood colon performance. we share control an test look at testing, For case to cancer data, providing
therapy colon release For to in for residual clinical cancer based MAP. help Cologuard test, support our to in selection, In and In validation top area validation leadership generate Oncotype from to to FDA tests cancer blood data announce of biopsy perspective colon testing, of a the disease approval we we test. cement study plan we tumor line our plan data screening. expect supporting blood X.X version clinical informed both liquid minimum BLUE-C results
a about expect depth breadth will This publication peer Liver our of and pipeline. reimbursement we published guideline Medicare the reviewed Oncoguard submission and support to We're in excited future manuscript Finally, be our inclusion. a journal.
help scientific tests diagnosis life continue energized their treatment. solutions bring Cologuard Exact to combined with will us in to our throughout new new Sciences several changing Our patients to cancer and team patients innovative is growing scale, need. capabilities The commercial and and provide Oncotype
the We're through foundation of now us power capabilities, achieve and happy our eradicating questions. to your Our relationships advanced of will take mission cancer analytics. help
